Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2018 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UNIFESP |
| Texto Completo: | http://dx.doi.org/10.1016/j.bcmd.2018.04.001 http://repositorio.unifesp.br/handle/11600/45968 |
Resumo: | Yale Univ, Sch Med, New Haven, CT USA |
| id |
UFSP_7907d1bb4a9799e46bbc008561c5f3bb |
|---|---|
| oai_identifier_str |
oai:repositorio.unifesp.br/:11600/45968 |
| network_acronym_str |
UFSP |
| network_name_str |
Repositório Institucional da UNIFESP |
| repository_id_str |
3465 |
| spelling |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Yale Univ, Sch Med, New Haven, CT USAIcahn Sch Med Mt Sinai, New York, NY 10029 USATechnion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Genet Inst, Rambam Hlth Care Campus, Haifa, IsraelHop La Rabta, Tunis, TunisiaUniv Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USANorthwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL 60611 USAEditas, Cambridge, MA USASanofi Genzyme, Cambridge, MA USAChristian Med Coll & Hosp, Vellore, Tamil Nadu, IndiaIMAI Res, Buenos Aires, DF, ArgentinaHosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, ArgentinaCairo Univ, Pediat Hematol, Cairo, EgyptHDES Hosp, Ponta Delgada, Acores, PortugalUniv Hosp Alexandrovska, Sofia, BulgariaDuke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USANatl Res Ctr Hematol, Moscow, RussiaHop Xavier Bichat, Paris, FranceUniv Fed Sao Paulo, Sao Paulo, SP, BrazilNYU, Sch Med, New York, NY USAUniv Belgrade, Sch Med, Clin Ctr Serbia, Belgrade, SerbiaRambam Med Ctr, Haifa, IsraelCedars Sinai, Tower Hematol Oncol, Beverly Hills, CA USAUniv Cambridge, Addenbrookes Hosp, Dept Med, Box 157,Level 5, Cambridge CB2 0QQ, EnglandUniv Fed Sao Paulo, Sao Paulo, SP, BrazilWeb of ScienceAcademic Press Inc Elsevier Science2018-07-26T12:18:27Z2018-07-26T12:18:27Z2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion71-74http://dx.doi.org/10.1016/j.bcmd.2018.04.001Blood Cells Molecules And Diseases. San Diego, v. 71, p. 71-74, 2018.10.1016/j.bcmd.2018.04.0011079-9796http://repositorio.unifesp.br/handle/11600/45968WOS:000432496500013enginfo:eu-repo/semantics/openAccessMistry, Pramod K.Balwani, ManishaBaris, Hagit N.Ben Turkia, HadhamiBurrow, T. AndrewCharrow, JoelCox, Gerald F.Danda, SumitaDragosky, MartaDrelichman, GuillermoEl-Beshlawy, AmalFraga, CristinaFreisens, SelenaGaemers, SebastiaanHadjiev, EvgueniyKishnani, Priya S.Lukina, ElenaMaison-Blanche, PierreMartins, Ana Maria [UNIFESP]Pastores, GregoryPetakov, MilanJudith Peterschmitt, M.Rosenbaum, HannaRosenbloom, BarryUnderhill, Lisa H.Cox, Timothy M.reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-02-13T21:31:26Zoai:repositorio.unifesp.br/:11600/45968Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652022-02-13T21:31:26Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
| dc.title.none.fl_str_mv |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| title |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| spellingShingle |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 Mistry, Pramod K. |
| title_short |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| title_full |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| title_fullStr |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| title_full_unstemmed |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| title_sort |
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1 |
| author |
Mistry, Pramod K. |
| author_facet |
Mistry, Pramod K. Balwani, Manisha Baris, Hagit N. Ben Turkia, Hadhami Burrow, T. Andrew Charrow, Joel Cox, Gerald F. Danda, Sumita Dragosky, Marta Drelichman, Guillermo El-Beshlawy, Amal Fraga, Cristina Freisens, Selena Gaemers, Sebastiaan Hadjiev, Evgueniy Kishnani, Priya S. Lukina, Elena Maison-Blanche, Pierre Martins, Ana Maria [UNIFESP] Pastores, Gregory Petakov, Milan Judith Peterschmitt, M. Rosenbaum, Hanna Rosenbloom, Barry Underhill, Lisa H. Cox, Timothy M. |
| author_role |
author |
| author2 |
Balwani, Manisha Baris, Hagit N. Ben Turkia, Hadhami Burrow, T. Andrew Charrow, Joel Cox, Gerald F. Danda, Sumita Dragosky, Marta Drelichman, Guillermo El-Beshlawy, Amal Fraga, Cristina Freisens, Selena Gaemers, Sebastiaan Hadjiev, Evgueniy Kishnani, Priya S. Lukina, Elena Maison-Blanche, Pierre Martins, Ana Maria [UNIFESP] Pastores, Gregory Petakov, Milan Judith Peterschmitt, M. Rosenbaum, Hanna Rosenbloom, Barry Underhill, Lisa H. Cox, Timothy M. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Mistry, Pramod K. Balwani, Manisha Baris, Hagit N. Ben Turkia, Hadhami Burrow, T. Andrew Charrow, Joel Cox, Gerald F. Danda, Sumita Dragosky, Marta Drelichman, Guillermo El-Beshlawy, Amal Fraga, Cristina Freisens, Selena Gaemers, Sebastiaan Hadjiev, Evgueniy Kishnani, Priya S. Lukina, Elena Maison-Blanche, Pierre Martins, Ana Maria [UNIFESP] Pastores, Gregory Petakov, Milan Judith Peterschmitt, M. Rosenbaum, Hanna Rosenbloom, Barry Underhill, Lisa H. Cox, Timothy M. |
| description |
Yale Univ, Sch Med, New Haven, CT USA |
| publishDate |
2018 |
| dc.date.none.fl_str_mv |
2018-07-26T12:18:27Z 2018-07-26T12:18:27Z 2018 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.bcmd.2018.04.001 Blood Cells Molecules And Diseases. San Diego, v. 71, p. 71-74, 2018. 10.1016/j.bcmd.2018.04.001 1079-9796 http://repositorio.unifesp.br/handle/11600/45968 WOS:000432496500013 |
| url |
http://dx.doi.org/10.1016/j.bcmd.2018.04.001 http://repositorio.unifesp.br/handle/11600/45968 |
| identifier_str_mv |
Blood Cells Molecules And Diseases. San Diego, v. 71, p. 71-74, 2018. 10.1016/j.bcmd.2018.04.001 1079-9796 WOS:000432496500013 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
71-74 |
| dc.publisher.none.fl_str_mv |
Academic Press Inc Elsevier Science |
| publisher.none.fl_str_mv |
Academic Press Inc Elsevier Science |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
| instname_str |
Universidade Federal de São Paulo (UNIFESP) |
| instacron_str |
UNIFESP |
| institution |
UNIFESP |
| reponame_str |
Repositório Institucional da UNIFESP |
| collection |
Repositório Institucional da UNIFESP |
| repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
| repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
| _version_ |
1814268434833211392 |